| Literature DB >> 31002104 |
Shannon M Casillas1, Rebecca L Hall1, Barbara L Herwaldt1.
Abstract
PROBLEM/CONDITION: Cyclosporiasis is an intestinal illness caused by the parasite Cyclospora cayetanensis, which is transmissible by ingestion of fecally contaminated food or water. Cyclosporiasis is most common in tropical and subtropical regions of the world. In the United States, foodborne outbreaks of cyclosporiasis have been linked to various types of imported fresh produce (e.g., basil, raspberries, and snow peas). Validated molecular typing tools, which could facilitate detection and investigation of outbreaks, are not yet available for C. cayetanensis. PERIOD COVERED: 2011-2015. DESCRIPTION OF SYSTEM: CDC has been conducting national surveillance for cyclosporiasis since it became a nationally notifiable disease in January 1999. As of 2015, cyclosporiasis was a reportable condition in 42 states, the District of Columbia, and New York City (NYC). Health departments voluntarily notify CDC of cases of cyclosporiasis through the National Notifiable Diseases Surveillance System and submit additional case information using the CDC cyclosporiasis case report form or the Cyclosporiasis National Hypothesis Generating Questionnaire (CNHGQ).Entities:
Mesh:
Year: 2019 PMID: 31002104 PMCID: PMC6476303 DOI: 10.15585/mmwr.ss6803a1
Source DB: PubMed Journal: MMWR Surveill Summ ISSN: 1545-8636
FIGURE 1Number of years of reportability for cyclosporiasis, by public health jurisdiction — United States, 2011–2015*
* Cyclosporiasis was a reportable condition in 39 jurisdictions (38 states and New York City) throughout the 5-year surveillance period. Cyclosporiasis was reportable in six jurisdictions during only part of the 5-year period (Alaska, 2013–2015; the District of Columbia, 2014–2015; Kentucky, 2015; Montana, 2013–2015; Oklahoma, 2011–2012; and Vermont, 2014–2015). Cyclosporiasis was not reportable in seven states (Alabama, Idaho, Maine, Mississippi, Nevada, North Dakota, and Pennsylvania) during any part of the 5-year period.
Number* and percentage† of reported cases of cyclosporiasis, by selected characteristics — United States, 2011–2015
| Characteristic | No. (%) |
|---|---|
|
| |
| Confirmed | 1,988 (90.1) |
| Probable | 219 (9.9) |
|
| |
| Male | 929 (42.1) |
| Female | 1,160 (52.6) |
| Unknown/Missing | 118 (5.3) |
|
| |
| 0–9 | 40 (1.8) |
| 10–19 | 61 (2.8) |
| 20–29 | 193 (8.7) |
| 30–39 | 334 (15.1) |
| 40–49 | 424 (19.2) |
| 50–59 | 499 (22.6) |
| 60–69 | 356 (16.1) |
| 70–79 | 143 (6.5) |
| ≥80 | 45 (2.0) |
| Unknown/Missing | 112 (5.1) |
|
| |
| American Indian/Alaska Native | 0 (0) |
| Asian/Pacific Islander | 18 (0.8) |
| Black | 40 (1.8) |
| White | 745 (33.8) |
| Other | 14 (0.6) |
| Unknown/Missing | 1,390 (63.0) |
|
| |
| Hispanic | 239 (10.8) |
| Non-Hispanic | 1,174 (53.2) |
| Unknown/Missing | 794 (36.0) |
|
| |
| New England | 98 (4.4) |
| Mid-Atlantic | 247 (11.2) |
| East North Central | 174 (7.9) |
| West North Central | 289 (13.1) |
| South Atlantic | 351 (15.9) |
| East South Central | 7 (0.3) |
| West South Central | 973 (44.1) |
| Mountain | 32 (1.4) |
| Pacific | 36 (1.6) |
* N = 2,207.
† Percentages might not total 100% because of rounding.
§ Confirmed: a case that meets the clinical description and at least one of the criteria for laboratory confirmation. Probable: a case that meets the clinical description and is epidemiologically linked to a confirmed case. Source: CDC. Cyclosporiasis (Cyclospora cayetanensis) 2010 Case Definition. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://wwwn.cdc.gov/nndss/conditions/cyclosporiasis/case-definition/2010/
¶ Cases were reported and totaled by state/area of residence, which might differ from location of exposure. Regions were defined as New England (Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont), Mid-Atlantic (New Jersey, New York, New York City, and Pennsylvania), East North Central (Illinois, Indiana, Michigan, Ohio, and Wisconsin), West North Central (Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota), South Atlantic (Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, and West Virginia), East South Central (Alabama, Kentucky, Mississippi, and Tennessee), West South Central (Arkansas, Louisiana, Oklahoma, and Texas), Mountain (Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, and Wyoming), and Pacific (Alaska, California, Hawaii, Oregon, and Washington).
Number* and incidence rate† of reported cases of cyclosporiasis, by state/area of residence§ and year¶ — United States, 2011–2015
| State/Area | 2011 | 2012 | 2013 | 2014 | 2015 | Total | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | |
| Alabama | —** | — | — | — | — | — | — | — | — | — |
|
| Alaska | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
|
| Arizona | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0.03 | 1 | 0.01 |
|
| Arkansas | 0 | 0 | 0 | 0 | 17 | 0.57 | 1 | 0.03 | 3 | 0.10 |
|
| California | 2 | 0.01 | 1 | <0.01 | 2 | 0.01 | 2 | 0.01 | 15 | 0.04 |
|
| Colorado | 0 | 0 | 1 | 0.02 | 1 | 0.02 | 1 | 0.02 | 8 | 0.15 |
|
| Connecticut | 10 | 0.28 | 6 | 0.17 | 3 | 0.08 | 8 | 0.22 | 16 | 0.45 |
|
| Delaware | 1 | 0.11 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.11 |
|
| District of Columbia | — | — | — | — | — | — | 0 | 0 | 0 | 0.00 |
|
| Florida | 61 | 0.32 | 25 | 0.13 | 47 | 0.24 | 33 | 0.17 | 32 | 0.16 |
|
| Georgia | 36 | 0.37 | 2 | 0.02 | 6 | 0.06 | 6 | 0.06 | 34 | 0.33 |
|
| Hawaii | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| Idaho | — | — | — | — | — | — | — | — | — | — |
|
| Illinois | 1 | 0 | 2 | 0.02 | 23 | 0.18 | 14 | 0.11 | 21 | 0.16 |
|
| Indiana | 26 | 0 | 0 | 0 | 1 | 0.02 | 2 | 0.03 | 0 | 0 |
|
| Iowa | 1 | 0.03 | 0 | 0 | 148 | 4.79 | 0 | 0 | 4 | 0.13 |
|
| Kansas | 0 | 0 | 0 | 0 | 4 | 0.14 | 1 | 0.03 | 6 | 0.21 |
|
| Kentucky | — | — | — | — | — | — | — | — | 0 | 0 |
|
| Louisiana | 1 | 0.02 | 1 | 0.02 | 3 | 0.06 | 0 | 0 | 1 | 0.02 |
|
| Maine | — | — | — | — | — | — | — | — | — | — |
|
| Maryland | 2 | 0.03 | 4 | 0.07 | 0 | 0 | 4 | 0.07 | 3 | 0.05 |
|
| Massachusetts | 6 | 0.09 | 1 | 0.02 | 5 | 0.07 | 18 | 0.27 | 21 | 0.31 |
|
| Michigan | 8 | 0.08 | 0 | 0 | 2 | 0.02 | 8 | 0.08 | 8 | 0.08 |
|
| Minnesota | 2 | 0 | 0 | 0 | 3 | 0.06 | 5 | 0.09 | 1 | 0.02 |
|
| Mississippi | — | — | — | — | — | — | — | — | — | — |
|
| Missouri | 1 | 0.02 | 2 | 0.03 | 5 | 0.08 | 1 | 0.02 | 5 | 0.08 |
|
| Montana | — | — | — | — | 0 | 0 | 2 | 0.20 | 3 | 0.29 |
|
| Nebraska | 1 | 0.05 | 0 | 0 | 91 | 4.87 | 3 | 0.16 | 4 | 0.21 |
|
| Nevada | — | — | — | — | — | — | — | — | — | — |
|
| New Hampshire | 0 | 0 | 0 | 0 | 1 | 0.08 | 0 | 0 | 3 | 0.23 |
|
| New Jersey | 9 | 0.10 | 7 | 0.08 | 13 | 0.15 | 16 | 0.18 | 21 | 0.23 |
|
| New Mexico | 1 | 0.05 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0.10 |
|
| New York†† | 30 | 0.15 | 21 | 0.11 | 21 | 0.11 | 37 | 0.19 | 72 | 0.36 |
|
| North Carolina | 1 | 0.01 | 2 | 0.02 | 0 | 0 | 4 | 0.04 | 4 | 0.04 |
|
| North Dakota | — | — | — | — | — | — | — | — | — | — |
|
| Ohio | 7 | 0.06 | 0 | 0 | 7 | 0.06 | 1 | 0.01 | 2 | 0.02 |
|
| Oklahoma | 0 | 0 | 0 | 0 | — | — | — | — | — | — |
|
| Oregon | 0 | 0 | 1 | 0.03 | 0 | 0 | 1 | 0.03 | 0 | 0 |
|
| Pennsylvania | — | — | — | — | — | — | — | — | — | — |
|
| Rhode Island | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| South Carolina | 1 | 0.02 | 0 | 0 | 0 | 0 | 18 | 0.37 | 2 | 0.04 |
|
| South Dakota | 0 | 0 | 0 | 0 | 1 | 0.12 | 0 | 0 | 0 | 0 |
|
| Tennessee | 2 | 0.03 | 2 | 0.03 | 1 | 0.02 | 1 | 0.02 | 1 | 0.02 |
|
| Texas | 18 | 0.07 | 51 | 0.20 | 362 | 1.37 | 200 | 0.74 | 315 | 1.15 |
|
| Utah | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.03 | 8 | 0.27 |
|
| Vermont | — | — | — | — | — | — | 0 | 0 | 0 | 0 |
|
| Virginia | 4 | 0.05 | 1 | 0.01 | 4 | 0.05 | 4 | 0.05 | 8 | 0.10 |
|
| Washington | 5 | 0.07 | 0 | 0 | 0 | 0 | 2 | 0.03 | 5 | 0.07 |
|
| West Virginia | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.05 | 0 | 0 |
|
| Wisconsin | 0 | 0 | 0 | 0 | 26 | 0.45 | 1 | 0.02 | 14 | 0.24 |
|
| Wyoming | 0 | 0 | 0 | 0 | 1 | 0.17 | 0 | 0 | 0 | 0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* N = 2,207.
† Incidence rate per 100,000 persons on the basis of U.S. intercensal state/area population estimates by year. Source: US Census Bureau. Annual estimates of the resident population: April 1, 2010 to July 1, 2017. Washington, DC: US Census Bureau; 2018. https://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?pid=PEP_2017_PEPANNRES&src=pt
§ Cases were reported by state/area of residence, which might differ from location of exposure. For the 2011–2015 surveillance period (year as reported by health department), CDC was notified of a total of 2,207 cases by 38 jurisdictions (37 states and New York City). Jurisdictions (50 states and the District of Columbia) are listed regardless of whether they notified CDC of any cases or whether cyclosporiasis was a reportable condition. Cases reported by New York State and New York City were totaled together for the purpose of the incidence calculations.
¶ Year as reported by health department.
** Not reportable.
†† Including New York City, which accounted for 124 (68.5%) of New York State’s 181 reported cases. New York City reported cases for all 5 surveillance years (19 for 2011, 16 for 2012, 15 for 2013, 23 for 2014, and 51 for 2015).
§§ Of the 237 total cases counted for 2011, 85 were probable cases associated with an outbreak in Georgia that were not reported in the National Notifiable Diseases Surveillance System (or included in case counts previously published [Source: CDC. MMWR: Summary of notifiable infectious diseases. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https://www.cdc.gov/mmwr/mmwr_nd/index.html]), which occurred among residents of 14 states, including the state of exposure. Ten additional probable cases associated with the same outbreak were not counted here: nine of these 10 occurred among residents of states in which cyclosporiasis was not a reportable condition, and the state of residence of the other patient was not known.
¶¶ For calculations of total annual incidence rates, the denominator comprised the sum of the populations of all of the states/areas in which cyclosporiasis was a reportable condition during the pertinent year.
Number* and percentage† of reported cases of cyclosporiasis, by state/area of residence§ and international travel history¶ — United States, 2011–2015
| State/Area (No. of yrs condition was reportable)** | Domestically acquired | Travel associated | Unknown travel history | Total |
|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | No. (%) | |
| Alabama (0) | —†† | — | — |
|
| Alaska (3) | 0 (0) | 0 (0) | 0 (0) |
|
| Arizona | 2 (0.1) | 1 (0.2) | 0 (0) |
|
| Arkansas | 15 (1.1) | 0 (0) | 6 (1.5) |
|
| California | 6 (0.4) | 11 (2.7) | 5 (1.2) |
|
| Colorado | 1 (0.1) | 7 (1.7) | 3 (0.7) |
|
| Connecticut | 19 (1.4) | 21 (5.1) | 3 (0.7) |
|
| Delaware | 0 (0) | 0 (0) | 2 (0.5) |
|
| District of Columbia (2) | 0 (0) | 0 (0) | 0 (0) |
|
| Florida | 127 (9.2) | 44 (10.6) | 27 (6.6) |
|
| Georgia | 42 (3.0) | 10 (2.4) | 32 (7.8) |
|
| Hawaii | 0 (0) | 0 (0) | 0 (0) |
|
| Idaho (0) | — | — | — |
|
| Illinois | 36 (2.6) | 12 (2.9) | 13 (3.2) |
|
| Indiana | 2 (0.1) | 0 (0) | 27 (6.6) |
|
| Iowa | 137 (9.9) | 4 (1.0) | 12 (2.9) |
|
| Kansas | 5 (0.4) | 2 (0.5) | 4 (1.0) |
|
| Kentucky (1) | 0 (0) | 0 (0) | 0 (0) |
|
| Louisiana | 5 (0.4) | 1 (0.2) | 0 (0) |
|
| Maine (0) | — | — | — |
|
| Maryland | 5 (0.4) | 6 (1.4) | 2 (0.5) |
|
| Massachusetts | 29 (2.1) | 9 (2.2) | 13 (3.2) |
|
| Michigan | 9 (0.7) | 2 (0.5) | 15 (3.7) |
|
| Minnesota | 7 (0.5) | 2 (0.5) | 2 (0.5) |
|
| Mississippi (0) | — | — | — |
|
| Missouri | 7 (0.5) | 5 (1.2) | 2 (0.5) |
|
| Montana (3) | 5 (0.4) | 0 (0) | 0 (0) |
|
| Nebraska | 53 (3.8) | 5 (1.2) | 41 (10.0) |
|
| Nevada (0) | — | — | — |
|
| New Hampshire | 4 (0.3) | 0 (0) | 0 (0) |
|
| New Jersey | 26 (1.9) | 31 (7.5) | 9 (2.2) |
|
| New Mexico | 2 (0.1) | 1 (0.2) | 0 (0) |
|
| New York State§§ | 25 (1.8) | 23 (5.5) | 9 (2.2) |
|
| New York City | 54 (3.9) | 58 (14.0) | 12 (2.9) |
|
| North Carolina | 1 (0.1) | 2 (0.5) | 8 (2.0) |
|
| North Dakota (0) | — | — | — |
|
| Ohio | 5 (0.4) | 2 (0.5) | 10 (2.5) |
|
| Oklahoma (2) | 0 (0) | 0 (0) | 0 (0) |
|
| Oregon | 0 (0) | 2 (0.5) | 0 (0) |
|
| Pennsylvania (0) | — | — | — |
|
| Rhode Island | 0 (0) | 0 (0) | 0 (0) |
|
| South Carolina | 15 (1.1) | 1 (0.2) | 5 (1.2) |
|
| South Dakota | 1 (0.1) | 0 (0) | 0 (0) |
|
| Tennessee | 1 (0.1) | 4 (1.0) | 2 (0.5) |
|
| Texas | 684 (49.4) | 130 (31.3) | 132 (32.4) |
|
| Utah | 3 (0.2) | 6 (1.4) | 0 (0) |
|
| Vermont (2) | 0 (0) | 0 (0) | 0 (0) |
|
| Virginia | 16 (1.2) | 3 (0.7) | 2 (0.5) |
|
| Washington | 3 (0.2) | 8 (1.9) | 1 (0.2) |
|
| West Virginia | 1 (0.1) | 0 (0) | 0 (0) |
|
| Wisconsin | 30 (2.2) | 2 (0.5) | 9 (2.2) |
|
| Wyoming | 1 (0.1) | 0 (0) | 0 (0) |
|
|
|
|
|
|
|
* N = 2,207.
† Percentages might not total 100% because of rounding.
§ Cases were reported by state/area of residence, which might differ from location of exposure. For the 2011–2015 surveillance period (year as reported by health department), CDC was notified of a total of 2,207 cases by 38 jurisdictions (37 states and New York City). Jurisdictions (50 states, the District of Columbia, and New York City) are listed regardless of whether they notified CDC of any cases or whether cyclosporiasis was a reportable condition.
¶ Cases were classified as travel associated or domestically acquired on the basis of the patient's travel history during the pertinent exposure period (i.e., the 14 days before illness onset). If the patient reported having a history of international travel (i.e., travel outside the United States) during all or part of the exposure period, the patient's case was classified as travel associated. If the patient reported having no history of international travel, the patient's case was classified as domestically acquired.
** The number of years that cyclosporiasis was a reportable condition in the listed jurisdiction if <5 years.
†† Not reportable.
§§ New York State exclusive of New York City.
Number* and percentage of reported cases of cyclosporiasis, by year† and international travel history§ — United States, 2011–2015
| Year(s) | Domestically acquired | Travel associated | Unknown travel history | Total |
|---|---|---|---|---|
| No. (%)¶ | No. (%) | No. (%) | No. (%) | |
| 2011 | 66 (27.8) | 60 (25.3) | 111 (46.8) |
|
| 2012 | 64 (49.2) | 34 (26.2) | 32 (24.6) |
|
| 2013 | 585 (73.3) | 44 (5.5) | 169 (21.2) |
|
| 2014 | 275 (69.1) | 77 (19.3) | 46 (11.6) |
|
| 2015 | 394 (61.2) | 200 (31.1) | 50 (7.8) |
|
|
|
|
|
|
|
* N = 2,207.
† Year as reported by health department.
§ Cases were classified as travel associated or domestically acquired on the basis of the patient's travel history during the pertinent exposure period (i.e., the 14 days before illness onset). If the patient reported having a history of international travel (i.e., travel outside the United States) during all or part of the exposure period, the patient's case was classified as travel associated. If the patient reported having no history of international travel, the patient's case was classified as domestically acquired.
¶ Percentages (per year[s]) in a row might not total 100% because of rounding.
FIGURE 2Number* of reported cases of cyclosporiasis, by year† and international travel history§ — United States, 2011–2015
* N = 2,207.
† Year as reported by health department.
§ Cases were classified as travel associated or domestically acquired on the basis of the patient’s travel history during the pertinent exposure period (i.e., the 14 days before illness onset). If the patient reported having a history of international travel (i.e., travel outside the United States) during all or part of the exposure period, the patient’s case was classified as travel associated. If the patient reported having no history of international travel, the patient’s case was classified as domestically acquired.
FIGURE 3Number* of reported cases of cyclosporiasis, by month of illness onset† and international travel history§ — United States, 2011–2015
* N = 2,004.
† Data regarding month of illness onset were available for most (90.8%, or 2,004 of 2,207) of the patients whose cases were reported to CDC (2011, 205 of 237; 2012, 112 of 130; 2013, 738 of 798; 2014, 356 of 398; and 2015, 593 of 644).
§ Cases were classified as travel associated or domestically acquired on the basis of the patient’s travel history during the pertinent exposure period (i.e., the 14 days before illness onset). If the patient reported having a history of international travel (i.e., travel outside the United States) during all or part of the exposure period, the patient’s case was classified as travel associated. If the patient reported having no history of international travel, the patient’s case was classified as domestically acquired.
Number of country visits for U.S. patients with travel-associated cases of cyclosporiasis and estimated percentages of overall U.S. outbound travel, by international destinations — United States, 2011–2015
| Destination* | Travel-associated cases with known travel destination(s) | U.S. outbound travel data¶ | |||
|---|---|---|---|---|---|
| Country visits | Also traveled elsewhere§ | ||||
| No. (%)† | No. | Estimated % of all travel | Period with available data | ||
| Mexico | 208 (63.6) | 6 | 36.0 | 2011–2015 | |
| Guatemala | 16 (4.9) | 1 | —** | — | |
| Dominican Republic | 15 (4.6) | 0 | 3.8 | 2012, 2014–2015 | |
| Cuba | 9 (2.8) | 1 | — | — | |
| Costa Rica | 5 (1.5) | 2 | 1.3 | 2011, 2014–2015 | |
| Haiti | 5 (1.5) | 1 | — | — | |
| India | 5 (1.5) | 0 | 1.6 | 2011–2015 | |
| Bahamas | 4 (1.2) | 1 | 1.6 | 2014–2015 | |
| China | 4 (1.2) | 2 | 1.8 | 2011–2015 | |
| Nicaragua | 4 (1.2) | 0 | — | — | |
| Puerto Rico | 4 (1.2) | 3 | — | — | |
| Other†† | 48 (14.7) | — | — | — | |
|
|
|
|
|
| |
* Among the 415 patients with travel-associated cases, some information about the destination of travel was known for 299 (72.0%). These 299 patients reportedly had a total of 327 country visits during the 14-day exposure period. For the purpose of these analyses, travel to a U.S. territory was classified as international. Destinations are listed in descending order, by the number of country visits.
† Percentages in this column do not total 100% because of rounding.
§ Among the 299 patients, 18 (6.0%) reported travel to more than one country: eight patients had traveled to two countries, and 10 patients had traveled to three.
¶ U.S. outbound travel estimates are based on data from the U.S. Department of Commerce, International Trade Administration, National Travel and Tourism Office (Source: National Travel and Tourism Office. 2015 U.S. resident travel abroad. Washington, DC: US Department of Commerce, International Trade Administration, National Travel and Tourism Office; 2016. https://travel.trade.gov/outreachpages/download_data_table/2015_US_Travel_Abroad.pdf). Travel estimates were unavailable if the sample size for a particular country/year was <400 respondents. The country-specific percentages were calculated by summing the number of country visits and dividing by the outbound visits to that country during the period(s) with available data.
** Not available or applicable.
†† Each of the specified destinations (or regions) of travel in the “other” category was associated with fewer than three patients. The destinations include 28 countries not listed. For two of the country visits, only region-level data were available (i.e., the Caribbean and Scandinavia). Overall, 287 (87.8%) of the 327 visits with at least region-level data were in the Americas, including Mexico (n = 208), the Caribbean (n = 43), Central America (n = 31), and South America (n = 5). The other 40 visits (12.2%) were elsewhere in the world, including Asia (n = 29), Europe (n = 9), and Africa (n = 2).